stockrow
Friday 6 November 2026
Export RCUS’s income statement to Excel — free account
Arcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
18.39
0.70
+3.96%
Follow RCUS
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
32.91 | 33.23 | 11.48 | 10.36 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(37.39) | (32.67) | (19.63) | (21.33) | |
P/B ratio |
9.19 | 8.38 | 5.17 | 4.06 | |
Price to Tangible BV |
9.19 | 8.38 | 5.17 | 4.06 | |
EV/Sales |
27.63 | 28.09 | 8.42 | 6.79 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.94) | (6.93) | (4.07) | (3.48) | |
EV/FCF |
(5.92) | (6.90) | (4.05) | (3.47) | |
Quick Ratio |
3.26 | 3.73 | 3.95 | 4.29 | |
Current Ratio |
3.34 | 3.82 | 4.04 | 4.36 | |
Net Debt/EBITDA |
0.00 | 6.26 | 5.35 | 7.74 | |
Debt/Assets |
12.47% | 10.93% | 10.03% | 8.69% | |
Debt/Equity |
0.28 | 0.22 | 0.19 | 0.16 | |
Asset Turnover |
0.11 | 0.12 | 0.22 | 0.22 | |
Operating CF/Net income |
0.69 | 1.31 | 1.08 | 1.13 | |
Capex/Depreciation |
— | — | 0.00 | 0.00 | |
Interest Coverage |
(43.67) | (32.00) | (44.67) | (57.00) | |
Research and Development Expense of Revenue |
1,300.00% | 275.61% | 717.65% | 366.67% | |
Selling, General and Administrative Expense of Revenue |
255.56% | 58.54% | 170.59% | 78.79% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
177.78% | 36.59% | 111.76% | 45.45% | |
Graham Net Nets |
0.06 | 0.08 | 0.14 | 0.20 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.05%) | (12.65%) | (14.72%) | (13.85%) | |
Free Cash Flow Yield |
(14.19%) | (12.24%) | (18.09%) | (18.91%) | |
Revenue per Share |
0.07 | 0.33 | 0.14 | 0.31 | |
Operating CF per Share |
(0.69) | (0.94) | (1.10) | (1.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.69) | (0.94) | (1.10) | (1.13) | |
Cash per Share |
4.95 | 5.57 | 6.56 | 9.13 | |
Shareholders Equity per Share |
2.81 | 3.68 | 4.18 | 5.88 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.81 | 3.68 | 4.18 | 5.88 | |
Free Cash Flow |
(88.00) | (119.00) | (138.00) | (121.00) | |
Working Capital |
465.00 | 558.00 | 635.00 | 776.00 | |
Capital Expenditures |
— | — | — | (1.00) | |
Net Current Asset Value |
204.00 | 296.00 | 371.00 | 499.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.50 | 25.50 | 9.00 | 15.50 | |
Average Payables |
43.00 | 31.50 | 30.50 | 30.00 | |
Average Assets |
896.00 | 999.50 | 1,076.50 | 1,144.50 | |
Average Common Equity |
397.00 | 506.50 | 527.50 | 558.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026